Category: News Items

ONL Therapeutics Closes Series A Financing to Support Development of Novel Retinal Cell Protection Platform for Treatment of Ocular Diseases Proceeds to Support Final Development of ONL1204 in Preparation for Retinal Detachment Clinical Trials ANN ARBOR, MI – May 17, 2017 ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a…

Novartis Steps in to Help Seed a Michigan Spinout’s Move into the Clinic with New Eye Drug Endpoints News Novartis has joined hands with some local investors in Michigan to come up with a small but significant $4.25 million A round… Read the Article

ONL Therapeutics Strengthens Leadership with Addition to Board of Directors and Expansion of Operations Team Company Names New Board Member, Continues to Build Out Operations Team Through Appointment and Promotions  ANN ARBOR, MI – March 28, 2017  ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases,…

ONL Therapeutics Gets Federal Grant of $1 Million Crain’s Company also raises $1 million to fund drug for patients with retinal detachments… Read the Article

After $1M NEI Grant, ONL Therapeutics Closer to Clinical Trials Xconomy ONL Therapeutics, the Ann Arbor, MI-based biotech startup working on sight-preserving therapies for patients with retinal diseases, is one step closer to clinical trials, thanks to a cash infusion from the National Eye Institute (NEI)…. Read the Article

Ocular Surgery NewsMay 18, 2017 ONL Therapeutics closes $4.25 million in Series A funding ONL Therapeutics has closed $4.25 million in Series A funding for preclinical development of its lead therapeutic candidate, ONL1204, designed to treat retinal detachment, according to a company press release. The funding, which came from investors including Novartis, the University of…

ONL Therapeutics Promotes New Lead Drug, Expands Clinical Program Xconomy Detroit – 7/6/15 by Sarah Schmid ONL Therapeutics, a University of Michigan spin-out working on sight-preserving therapies for retinal diseases, announced that it has changed course in its drug development program. The company has promoted a new lead drug candidate and has expanded its planned clinical studies to…

ONL Therapeutics Receives Phase II SBIR Grant from National Eye Institute for Development of Novel Retinal Disease Treatment ANN ARBOR, MI – November 12, 2014 ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today announced that the company has been awarded a $1.37 million Small…

SBIR Award, $1M Investment Get ONL Therapeutics to Clinical Trials Xconomy Detroit – 11/12/14 by Sarah Schmid ONL Therapeutics, a University of Michigan spin-out biopharmaceutical startup working on sight-preserving therapies for retinal diseases, announced today that it has won a $1.3 million Small Business Innovation Research (SBIR) Phase II award from the National Eye Institute. Read the Article